191 related articles for article (PubMed ID: 27470427)
1. Measuring the subjective: revisiting the psychometric properties of three rating scales that assess the acute effects of hallucinogens.
Bouso JC; Pedrero-Pérez EJ; Gandy S; Alcázar-Córcoles MÁ
Hum Psychopharmacol; 2016 Sep; 31(5):356-72. PubMed ID: 27470427
[TBL] [Abstract][Full Text] [Related]
2. Psychometric assessment of the Hallucinogen Rating Scale.
Riba J; Rodríguez-Fornells A; Strassman RJ; Barbanoj MJ
Drug Alcohol Depend; 2001 May; 62(3):215-23. PubMed ID: 11295326
[TBL] [Abstract][Full Text] [Related]
3. Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT.
Griffiths RR; Hurwitz ES; Davis AK; Johnson MW; Jesse R
PLoS One; 2019; 14(4):e0214377. PubMed ID: 31013281
[TBL] [Abstract][Full Text] [Related]
4. Pharmacology of ayahuasca administered in two repeated doses.
Dos Santos RG; Grasa E; Valle M; Ballester MR; Bouso JC; Nomdedéu JF; Homs R; Barbanoj MJ; Riba J
Psychopharmacology (Berl); 2012 Feb; 219(4):1039-53. PubMed ID: 21842159
[TBL] [Abstract][Full Text] [Related]
5. Dark Classics in Chemical Neuroscience: N, N-Dimethyltryptamine (DMT).
Cameron LP; Olson DE
ACS Chem Neurosci; 2018 Oct; 9(10):2344-2357. PubMed ID: 30036036
[TBL] [Abstract][Full Text] [Related]
6. Ayahuasca: Psychological and Physiologic Effects, Pharmacology and Potential Uses in Addiction and Mental Illness.
Hamill J; Hallak J; Dursun SM; Baker G
Curr Neuropharmacol; 2019; 17(2):108-128. PubMed ID: 29366418
[TBL] [Abstract][Full Text] [Related]
7. Modulatory effects of ayahuasca on personality structure in a traditional framework.
Netzband N; Ruffell S; Linton S; Tsang WF; Wolff T
Psychopharmacology (Berl); 2020 Oct; 237(10):3161-3171. PubMed ID: 32700023
[TBL] [Abstract][Full Text] [Related]
8. Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine.
Dos Santos RG; Valle M; Bouso JC; Nomdedéu JF; Rodríguez-Espinosa J; McIlhenny EH; Barker SA; Barbanoj MJ; Riba J
J Clin Psychopharmacol; 2011 Dec; 31(6):717-26. PubMed ID: 22005052
[TBL] [Abstract][Full Text] [Related]
9. Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteers.
Riba J; Rodríguez-Fornells A; Urbano G; Morte A; Antonijoan R; Montero M; Callaway JC; Barbanoj MJ
Psychopharmacology (Berl); 2001 Feb; 154(1):85-95. PubMed ID: 11292011
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant Effects of a Single Dose of Ayahuasca in Patients With Recurrent Depression: A SPECT Study.
Sanches RF; de Lima Osório F; Dos Santos RG; Macedo LR; Maia-de-Oliveira JP; Wichert-Ana L; de Araujo DB; Riba J; Crippa JA; Hallak JE
J Clin Psychopharmacol; 2016 Feb; 36(1):77-81. PubMed ID: 26650973
[TBL] [Abstract][Full Text] [Related]
11. Effects of the South American psychoactive beverage ayahuasca on regional brain electrical activity in humans: a functional neuroimaging study using low-resolution electromagnetic tomography.
Riba J; Anderer P; Jané F; Saletu B; Barbanoj MJ
Neuropsychobiology; 2004; 50(1):89-101. PubMed ID: 15179026
[TBL] [Abstract][Full Text] [Related]
12. Topographic pharmaco-EEG mapping of the effects of the South American psychoactive beverage ayahuasca in healthy volunteers.
Riba J; Anderer P; Morte A; Urbano G; Jané F; Saletu B; Barbanoj MJ
Br J Clin Pharmacol; 2002 Jun; 53(6):613-28. PubMed ID: 12047486
[TBL] [Abstract][Full Text] [Related]
13. Dimethyltryptamine (DMT): subjective effects and patterns of use among Australian recreational users.
Cakic V; Potkonyak J; Marshall A
Drug Alcohol Depend; 2010 Sep; 111(1-2):30-7. PubMed ID: 20570058
[TBL] [Abstract][Full Text] [Related]
14. Health status of ayahuasca users.
Barbosa PC; Mizumoto S; Bogenschutz MP; Strassman RJ
Drug Test Anal; 2012; 4(7-8):601-9. PubMed ID: 22761152
[TBL] [Abstract][Full Text] [Related]
15. Dose-response study of N,N-dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.
Strassman RJ; Qualls CR; Uhlenhuth EH; Kellner R
Arch Gen Psychiatry; 1994 Feb; 51(2):98-108. PubMed ID: 8297217
[TBL] [Abstract][Full Text] [Related]
16. Human psychopharmacology of N,N-dimethyltryptamine.
Strassman RJ
Behav Brain Res; 1996; 73(1-2):121-4. PubMed ID: 8788488
[TBL] [Abstract][Full Text] [Related]
17. Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users.
Ona G; Kohek M; Massaguer T; Gomariz A; Jiménez DF; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC
J Psychoactive Drugs; 2019; 51(2):135-145. PubMed ID: 30732540
[TBL] [Abstract][Full Text] [Related]
18. Acute Psychological Adverse Reactions in First-Time Ritual Ayahuasca Users: A Prospective Case Series.
Gómez-Sousa M; Jiménez-Garrido DF; Ona G; Dos Santos RG; Hallak JEC; Alcázar-Córcoles MÁ; Bouso JC
J Clin Psychopharmacol; 2021 Mar-Apr 01; 41(2):163-171. PubMed ID: 33606432
[TBL] [Abstract][Full Text] [Related]
19. Effects of ayahuasca on psychometric measures of anxiety, panic-like and hopelessness in Santo Daime members.
Santos RG; Landeira-Fernandez J; Strassman RJ; Motta V; Cruz AP
J Ethnopharmacol; 2007 Jul; 112(3):507-13. PubMed ID: 17532158
[TBL] [Abstract][Full Text] [Related]
20. Altered State of Consciousness and Mental Imagery as a Function of N, N-dimethyltryptamine Concentration in Ritualistic Ayahuasca Users.
Ramaekers JG; Mallaroni P; Kloft L; Reckweg JT; Toennes SW; van Oorsouw K; Mason NL
J Cogn Neurosci; 2023 Sep; 35(9):1382-1393. PubMed ID: 37159257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
